Technosphere insulin and Degludec non-inferior to usual care for postprandial hyperglycemia in T1 Diabetics: Study
A recent study published in the journal Diabetes Care found that the combination of Technosphere insulin (TI) plus insulin degludec is non-inferior to the usual care of an automated insulin delivery (AID) system or multiple daily insulin injections (MDI) for controlling postprandial diabetes in individuals with Type 1 diabetes.
Only a limited proportion of adults with type 1 diabetes meet the Glycemic targets set by the American Diabetes Association. The delayed onset of rapid-acting analog (RAA) insulin makes it difficult for Automated insulin delivery (AID) systems to prevent hyperglycemia. Inhaled Technosphere insulin (TI) is better at offering faster onset and dissipation, reducing post-meal hyperglycemia and hypoglycemia risk. Despite the drug's limited use, despite FDA approval, trials comparing TI with traditional insulin regimens were done. Researchers from the U.S.A. conducted a study to evaluate a regimen of inhaled Technosphere insulin (TI) plus insulin degludec in adults with type 1 diabetes, who were predominately using either an automated insulin delivery (AID) system or multiple daily insulin injections (MDI) with continuous glucose monitoring before participating in the study.
A randomized trial was conducted at 19 endocrinology practices in the U.S., including individuals aged ≥18 years old with type 1 diabetes for at least 6 months. Inclusion criteria were adhering to the same treatment regimen for at least 3 months, like the AID nonautomated pump, or MDI, and having an HbA1c level < 11.0%. Eligible participants were randomly assigned (1:1) with the use of a block design separately for each site to either the TI-degludec regimen or the usual care (UC) group. HbA1c was measured at baseline and after 17 weeks, along with forced expiratory volume in 1 s, continuous glucose monitoring (CGM), and a patient-reported outcome survey.
Findings:
- AID was used by 48% and MDI by 45% before the study.
- Mean ± SD HbA1c was 7.57% ± 0.97% at baseline and 7.62% ± 1.06% at 17 weeks in the TI group.
- Mean ± SD HbA1c was 7.59% ± 0.80% at baseline and 7.54% ± 0.77% at 17 weeks in the UC group.
- In the TI group, HbA1c improved by >0.5% from baseline to 17 weeks in 21 % of the participants and 5% of them in the UC group.
- In the UC group, HbA1c worsened by >0.5% from baseline to 17 weeks in 26% of the TI group and 3% of the UC group.
- The most common TI side effect was a brief cough.
- About eight participants discontinued TI due to side effects.
Thus, the study concluded that TI and degludec were non-inferior to UC. A similar number of participants showed improvements and worsening of glycemic control, so self-management of TI with degludec is necessary with free frequent TI inhalation during the day and evening. The researchers also suggested that TI with degludec can be used as a viable option for patients with type 1 diabetes. Hence, clinicians should carefully select the patients while prescribing this combination for optimal glycemic control.
Further reading: A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes. Doi: https://doi.org/10.2337/dc24-1832.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.